Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    GeneDx Corp.

    NASDAQ: WGS · Real-Time Price · USD
    124.25
    1.37 (1.11%)
    At close: Aug 15, 2025, 10:17 AM
    1.11%
    Bid 123.82
    Market Cap 3.57B
    Revenue (ttm) 362.32M
    Net Income (ttm) 1.41M
    EPS (ttm) 0.07
    PE Ratio (ttm) 1775
    Forward PE 44.97
    Analyst Buy
    Ask 124.5
    Volume 168,077
    Avg. Volume (20D) 903,720
    Open 124.16
    Previous Close 122.88
    Day's Range 121.00 - 125.00
    52-Week Range 28.86 - 125.00
    Beta 2.08

    About WGS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol WGS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for WGS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    GeneDx Corp. is scheduled to release its earnings on Oct 28, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 weeks ago
    +12.78%
    GeneDx Holdings shares are trading higher after We... Unlock content with Pro Subscription
    2 weeks ago
    +8.09%
    GeneDx shares are trading higher after the company raised FY25 sales guidance above estimates.
    news image

    4 days ago · zacks.com

    Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates?

    GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    news image

    1 week ago · zacks.com

    Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?

    GeneDx Holdings Corp. (WGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, WGS's 50-day simple moving average broke out above its 2...

    news image

    1 week ago · businesswire.com

    GeneDx to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.

    news image

    2 weeks ago · seekingalpha.com

    GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth

    GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement ra...

    news image

    2 weeks ago · fool.com

    Why GeneDx Holdings Stock Crushed It Again Today

    GeneDx (WGS 12.78%) shareholders are having quite a spectacular week, and it's not over yet. On Wednesday, the company's stock soared again, notching a nearly 13% pop after the previous day's 8%-plus ...

    2 weeks ago · youtube.com

    GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options

    Katherine Stueland, GeneDx CEO, joins 'Squawk Box' to discuss diagnosing children with rare diseases, cost structure of the tests, the fight against rare diseases, company growth outlook, deployment o...

    news image

    2 weeks ago · fool.com

    Why GeneDx Holdings Stock Blasted 8% Higher Today

    The stock of genetic testing company GeneDx Holdings (WGS 8.09%) was quite the hot item on the second trading day of the week. After the company published an encouraging second-quarter earnings report...

    news image

    2 weeks ago · seekingalpha.com

    GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript

    GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Offi...

    news image

    2 weeks ago · zacks.com

    WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View

    GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.

    news image

    2 weeks ago · zacks.com

    GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates

    GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago.

    Add to Watchlist